High-temperature-required protein A2 as a predictive marker for response to chemotherapy and prognosis in patients with high-grade serous ovarian cancers.
Br J Cancer
; 112(4): 739-44, 2015 Feb 17.
Article
en En
| MEDLINE
| ID: mdl-25628093
ABSTRACT
BACKGROUND:
High-temperature-required protein A2 (HtrA2), a protein relating with apoptosis in a caspases-dependent and non-dependent manner, has been reported to be associated with chemosensitivity in several human cancers.METHODS:
Tissue microarrays made from 142 patients with high-grade serous ovarian adenocarcinoma were evaluated to assess whether HtrA2 expression was related with several clinical parameters.RESULTS:
Negative HtrA2 expression was observed in 36 cases (25%) of the patients, and related with significantly lower response rates of primary chemotherapy than those with positive HtrA2 expression (56% vs 83%, P<0.01). In addition, negative HtrA2 expression was identified as an independent worse prognostic factor for progression-free survival and overall survival by multivariate analyses. Furthermore, HtrA2 downregulation modulated sensitivity to platinum in serous ovarian cancer cells in vitro.CONCLUSIONS:
HtrA2 expression was a predictor for sensitivity to chemotherapy, and could be a candidate of molecular target in the treatment of high-grade serous ovarian cancers.
Texto completo:
1
Colección:
01-internacional
Asunto principal:
Neoplasias Ováricas
/
Serina Endopeptidasas
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Biomarcadores de Tumor
/
Cistadenocarcinoma Seroso
/
Proteínas Mitocondriales
Tipo de estudio:
Prognostic_studies
/
Risk_factors_studies
Límite:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Middle aged
Idioma:
En
Revista:
Br J Cancer
Año:
2015
Tipo del documento:
Article
País de afiliación:
Japón